ERBB2 and breast carcinoma: The downregulation of MALAT1 enhanced trastuzumab-inhibiting cell viability and reduced the number of invaded cells, suggesting a potential role for MALAT1 in decreasing sensitivity of trastuzumab in HER2+ breast cancer cells.